RBC Bioscience Profit Margin

RBC Bioscience (6848.TWO) currently reports a profit margin of 9.62% as of June 2026. That compares with 4.18% in the prior-year period — up 130.3% year over year. That is above the Healthcare sector average of 9.48%. Use the charts on this page to explore RBC Bioscience's profit margin history and peer comparisons.

RBC Bioscience's profit margin increased from 4.18% to 9.62% — a 130.3% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

RBC Bioscience's profit margin of 9.62% is higher than the Healthcare sector average of 9.48%. That is roughly 1.5% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but RBC Bioscience's current 9.62% should be judged against Healthcare norms (sector average: 9.48%) and against 6848.TWO's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of 9.62%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 9.48%. From there, open related valuation or income-statement pages for RBC Bioscience, and consider following 6848.TWO for alerts when major investors trade the stock.